

RFA: High Enrolling Clinical Trial Operational Support

Background: UNC Lineberger has a catchment area that spans all 100 counties of North Carolina (NC) allowing for research to reach all NC residents. Lineberger Comprehensive Cancer Center (LCCC) is the only public NCI-designated cancer center in the state.

RFA Focus: The focus of this RFA is on cancer clinical trials that are considered to be interventional and require funding to support personnel to run the trials. This may include “next to standard of care (SOC)” trials, which are defined as trials that may be evaluating current SOC practices or treatments for which little research data exists or for studies with slight variations in standard of care treatments or practices. This RFA is for single center studies including hybrid decentralized trials where some or all of the trial-related activities occur at UNC Cancer Hospital.

Priority will be given to projects that:

- Would be considered interventional and/or treatment trials by NCI definition: <https://cancercenters.cancer.gov/GrantsFunding/DataGuide#dt4>
- Address treatment disparities
- Anticipate accrual of 100 or more subjects per year
- Collaborative projects across disease groups or other research programs within LCCC

Clinical Trial topics of interest may include, but are not limited to, the following:

- Drug treatment trials
- Prospective biomarker trials (including liquid biopsy)
- Studies that contain elements to address inequities in care
- Patient experience
- Treatment implications for obese patients

LOI:

Applicants should submit a 500 word maximum letter of interest (LOI) by 11/01/2023 to Mac Robinson (Mac_Robinson@med.unc.edu) to allow for initial evaluation and consultation related to the proposed project. Some of the topics that may fall under the purview of an LOI consultation include but are not limited to the following:

- Hybrid decentralized approaches
- Statistical consultation
- Matters to address equitable inclusion
- Trial design strategies

Project parameters:

Proposed studies should be completed within 2 years of award. Two awards will be granted with funding provided in the form of clinical operations (study coordinator), regulatory and monitoring personnel support.

RFA Submission Period:

The formal RFA submission period will be from 10/15/2023 to 11/15/2023.

RFA Review and Award Notification Period:

RFAs will be reviewed from 11/15/2023 to 12/15/2023 and award notices will be distributed 01/15/2024.